



Mouse Anti-Omalizumab monoclonal antibody, clone 21H4 (CABT-ZB225)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB225 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Omalizumab.
Specificity	The product is specific for Omalizumab.
Target	Omalizumab
Immunogen	Omalizumab
Isotype	IgG1, κ
Source/Host	Mouse
Clone	21H4
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB225 - CABT-ZB226 Recommended Working Concentration: 0.005-0.1 µg/ml
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg

Buffer	Lyophilized with PBS, pH 7.2, contains 0.02% sodium azide.
Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Omalizumab with trade name Xolair, is an FDA-approved drug for the treatment of moderate to severe persistent asthma in adults and adolescents (12 years of age and above). It is a recombinant humanized monoclonal antibody. It selectively binds to human immunoglobulin E (IgE). Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils.
Keywords	Mouse monoclonal antibody to Omalizumab/Xolair; Omalizumab; Xolair

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Omalizumab/Xolair; Omalizumab; Xolair
-----------------	--